I realize that I have been blogging about adverse events for the past couple of day but, let’s face it; the pharmaceutical industry lives or dies by the number of adverse events (AEs) that are reported for approved and marketed drugs. In any event, I came upon [...]
Opexa Therapeutics (NASDAQ:OPXA) shares were battered as the company went to market to raise cash.
The firm said it entered into definitive agreements with institutional investors in a direct placement with gross proceeds of $5.1 million. The offering is made pursuant to the Form S-3 shelf registration statement that was filed by [...]
Oncothyreon (NASDAQ:ONTY) shares jumped as the firm announced that Merck KGaA has initiated a Phase 3 trial of Stimuvax (BLP25 liposome vaccine) in Asian patients with advanced non-small cell lung cancer (NSCLC). The trial, named INSPIRE (Stimuvax trial In Asian NSCLC Patients: Stimulating Immune Response), is anticipated to enroll approximately 420 [...]
Professor Vincent Racaniello, a BioCrowd co-founder, blogger and host of the increasingly popular This Week in Virology (TWIV) podcast series made an anguished plea in a recent post on his Virology Blog to help promote American science literacy. “If you are writing a book, article, [...]
Everyone wants to know which stocks in biotech and medical technology will be the next buyout target. It is rare that research reports or interviews from traditional brokerage firms point out an obvious takeover candidate, but that is exactly what came about in shares of Affymetrix Inc. (NASDAQ: AFFX) this [...]
.jpg)
